Bizarre paper [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-06-08 12:43  – Posting: # 21510
Views: 3,444

Hi Nastia,

THX for the paper! 1
Regrettably the authors got many things wrong. The FDA does not require AUC0–t or AUC0–∞ but both. Reading educates.
The infamous AUCall is nowhere recommended in the Japanese Guideline 2 (AUCt as everywhere else). Given, the “80% rule” is mentioned as well. The Q&A 3 is more specific and states in A-28:

AUC is calculated by a trapezoidal rule as the area under the straight lines connecting the measured points.

(my emphasis)
OK, the bloody linear trapezoidal but can we measure zero? Nope.

Hence this one

[image]


as the base of all simulations is already wrong and IMHO, the article missed the point.
BTW, this figure is extremely funny cause AUCall is >100% of AUCinf. Rule fulfilled → tick the box → mission accomplished. :crying: LLOQ 17% of Cmax, fantastic bioanalytics.
This example demonstrates that setting the first value after tlast to zero is nonsense. I have seen splendid rules like “set first one after tlast to LLOQ/2 and keep subsequent ones as BQL”. Here also >100% of AUCinf. Forget it.


  1. Oishi M, Chiba K, Fukushima T, Tomono Y, Suwa T. Different truncation methods of AUC between Japan and the EU for bioequivalence assessment: influence on the regulatory judgment. Drug Metab Pharmacokinet. 2012;27(6):658‐662. doi:10.2133/dmpk.DMPK-12-RG-033.
  2. PMDA. Guideline for Bioequivalence Studies of Generic Products. Feb 29, 2012.
  3. PMDA. Q&A. Feb 29, 2012.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,801 posts in 4,354 threads, 1,446 registered users;
online 18 (0 registered, 18 guests [including 5 identified bots]).
Forum time: 09:06 CEST (Europe/Vienna)

Medical statistician: One who will not accept that Columbus discovered America…
because he said he was looking for India in the trial plan.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5